Epidural Stimulation for Upper Extremity Function
- Conditions
- TetraplegiaSpinal Cord Injury Cervical
- Interventions
- Device: Percutaneous spinal cord stimulation
- Registration Number
- NCT06437548
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
Restoring upper extremity function in patients with cervical spinal cord injury is extremely important for patients' independence and quality of life.
At present, there are limited options for hand or arm reanimation in this patient population. Nerve transfer is one such option that can partially restore the natural movement of hand or arm function in select patients.
The investigators are interested in understanding whether recovery of hand or arm motor function after nerve transfer can be augmented by cervical epidural spinal cord stimulation.
- Detailed Description
The study will enroll up to 20 participants in a single arm prospective clinical study. Potential participants will have already had a nerve transfer surgery more than 6 months prior to enrollment and will have also completed post-nerve transfer physical /occupational neurorehabilitation.
At baseline, upper extremity muscle strength, muscle force and nerve health with needle electromyography and neuroimaging will be tested.
Patients will undergo percutaneous (temporary) spinal cord stimulator leads placement in the cervical supralesional spine region.
Week 0-4: Weekly testing of motor function and muscle contraction force with the stimulation turned on versus turned off will be performed. Stimulation parameters for each target upper extremity muscle will also be documented.
Temporary leads will be removed after approximately 4 weeks.
At the last research visit at approximately 6-7 weeks post leads placement muscle strength/force will be assessed to determine the duration of the stimulation effect (if it is sustained). To assess any improvement of nerve health, neuroimaging and electromyography will also be performed.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 20
- Age ≥18 years and ≤65
- Provides informed consent
- History of upper extremity nerve transfer > 6 months prior to enrollment
- Completion of standard post-nerve transfer occupational therapy
- Baseline upper extremity strength of < 5/5 grade with the MRC
- Scheduled to undergo a cervical spinal cord stimulation procedure for chronic pain refractory to first line therapy
- Willing and able to adhere to the study protocol
- Central nervous system (CNS) malignancy
- A contraindication to the SCS procedure
- Diagnosis that precludes the patient from full participation in the protocol
- A functional implanted device (pacemaker, vagus nerve device, baclofen pump)
- Botulinum toxin injection in upper extremity muscles < 6 months prior to enrollment
- For female participants, current/planned pregnancy (females of childbearing age will be asked to take a pregnancy test on the day of the intervention)
- Other factors that prevent participation in the opinion of the surgeon-principal investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Percutaneous spinal cord stimulation Percutaneous spinal cord stimulation All participants will undergo baseline muscle strength and force assessments. Participants will also answer questionnaires on pain and quality of life. An optional nerve health assessment with needle electromyography and neuroimaging may be performed. Participants will undergo clinically indicated percutaneous (temporal) cervical epidural leads placement. Weeks 0-4 post-leads placement: during weekly visits upper extremity muscle strength and force will be assessed, pain and quality of life questionnaires will be completed (1 research visit per week) At approximately 28 days temporary leads will be removed. At the last visit, muscle strength and force in upper extremity muscle groups will be assessed, participants will complete pain and quality of life questionnaires. Participants may choose to undergo an optional nerve health assessment with needle electromyography and neuroimaging.
- Primary Outcome Measures
Name Time Method Nerve transfer recipient muscle strength 0-6 weeks Change in Medical Research Council (MRC) grade of recipient nerve transfer muscle group with spinal cord stimulation activated. MRC ranges from 0 (no visible muscle contraction) to 5 (normal muscle strength against full resistance). A larger number represents a better outcome.
- Secondary Outcome Measures
Name Time Method Nerve transfer recipient muscle force 0-6 weeks Change in muscle force generated by recipient nerve transfer muscle group with spinal cord stimulation activated. Muscle force is measured with a hand-held dynamometer. This is measured in Newtons, with a larger number meaning greater force and a better outcome.
Frequency of percutaneous stimulation 0-4 weeks Optimized frequency of percutaneous stimulation for each upper extremity muscle for voluntary hand/arm motor function will be documented. Frequency is measured in Hz (Hertz).
Neck and upper extremity pain 0-6 weeks Change in neck and upper extremity pain measured with the Numeric Rating Scale (NRS). NRS scale ranges from 0 (No pain) to 10 (worst possible pain), with a lower number representing a better outcome. A positive change in NRS from baseline to follow-up visits suggests improvement of pain.
Amplitude of percutaneous stimulation 0-4 weeks Optimized amplitude of percutaneous stimulation for each upper extremity muscle for voluntary hand/arm motor function will be documented. Amplitude is measured in miliAmperes.
Pulse width of percutaneous stimulation 0-4 weeks Optimized pulse width of percutaneous stimulation for each upper extremity muscle for voluntary hand/arm motor function will be documented. Pulse width is measured in microseconds.